KārlisPleiko

[vittorio @IterIntellectus]

they fucking did it

they genetically edited mosquitoes so they can’t transmit malaria.
and made the mutation self-replicating.

edited mosquitoes and every descendant can’t infect humans.

[KārlisPleiko @PleikoKarlis]

Kopš marta @osi_lv sadarbībā ar @unitartu Bio- un Translācijas Medicīnas institūtu īstenoju postdoc projektu “AptaPhage – fāgu displeja tehnoloģija aptamēru atlasei” (Nr. 1.1.1.9/LZP/1/24/049). Paldies par piešķirto atbalstu @Zinatnespadome !

[KārlisPleiko @PleikoKarlis]

Presentations are a disease. Just share the protocol

[Nature Reviews Drug Discovery @NatRevDrugDisc]

In vivo CAR T cells move into clinical trials https://t.co/33k0MSXBaL

Find out how drug developers are aiming to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity in this news article published today

[Guntars Kitenbergs @guntarskit]

Kā mums izdodas sačakarēt labas zinātnes iniciatīvas ar birokrātiskiem brīnumiem? Ar šodienu #PostDocLatvia projektos sagaida max 3 gadus + 1 pašu finansētu gadu (lai arī tipiski ārzemēs PostDoc ir īss projekts ar skaidru finansējumu). 1/2

[Guntars Kitenbergs @guntarskit]

Izsludināts pirmais "jaunā" #PostDocLatvia konkurss. Var kandidēt visi, kam Phd <10 gadiem, budžets ~90 projektiem uz 3 gadiem ar algu ~3120 EUR/mēn (bruto). Tematikai jāatbilst RIS3. 2 mēneši laika pieteikumu sagatavošanai. Veiksmi! Viss info te: https://t.co/0BmC6Wu5lx

[Vic 📠 @VicVijayakumar]

born to say "wtf why did you do this"

forced to say "can i please get more context on this decision"

[Andy Vaughan also on bluesky @vaughandy]

For the love of God people just do some experiments, enough with the single cell seq atlases

[Demis Hassabis @demishassabis]

Thrilled to announce AlphaFold 3 which can predict the structures and interactions of nearly all of life’s molecules with state-of-the-art accuracy including proteins, DNA and RNA. Biology is a complex dynamical system so modeling interactions is crucial https://t.co/Gs4GoOB3fD

[Latvijas Jauno zinātnieku apvienība @LV_JZA]

Ieguldīt pētniecībā un inovācijā nozīmē ieguldīt nākotnē - LJZA sarunājas ar @ivarsbu https://t.co/5qA4DGEbH3 Foto Gatis Šļūka / Latvijas Mediji @KarikaturaLv

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Strategies to improve the systemic distribution of siRNA drugs and promote efficacy in tissues beyond the liver include conjugation to lipids or targeting entities such as antibodies - find out more in this Review https://t.co/3XTYd2SBB0

[The Lucks Lab @LucksLab]

(1/3) Excited to share our newest publication!! Fun collaboration with the Chen and Severinov labs to investigate how the fluoride riboswitch rearranges a pseudoknot to form a terminator. See movie generated by @elisew00 and Alan Chen (@TheRNAInstitute)

https://t.co/xrf8Zofh8Q

[Simon Duerr @simonduerr]

I have created Bioicons - a library of 1632+ free, high quality science illustrations in vector format easily searchable and filterable specifically for the life science community. All icons are under permissive CC0 or CC BY license. ➡️ https://t.co/H7CawgOOiJ

[FierceBiotech @FierceBiotech]

Novartis is adding another weapon to its arsenal of oncology therapies, paying Arvinas $150 million upfront for rights to a phase 3-ready protein degrader that could treat a wide range of prostate cancer patients.
https://t.co/9VAOPZ7b7n

[Nature Biotechnology @NatureBiotech]

The US FDA approved a record-breaking 71 new drugs in 2023, which may help assuage concerns of a more restrictive regulator and signal a back-to-business FDA following the end of the US COVID-19 public health emergency https://t.co/qE2rWqT9pv
https://t.co/nQ0NVXDIKW

[Nature Biotechnology @NatureBiotech]

AlphaFold2 and RoseTTAFold are limited to predicting the 3D structure of proteins. A new all-atom method models complete biomolecular assemblies, including proteins, nucleic acids, small molecules, metals, and covalent modifications. #NBThighlight https://t.co/a9relIlKLC

[Nature Biotechnology @NatureBiotech]

RNA interference in the era of nucleic acid therapeutics https://t.co/WvhmF0wUvq

[Serpell Lab Reads @SerpellLabReads]

Cancer-targeting antibody–drug conjugates drive dealmaking frenzy https://t.co/msegfQRefh

[Dr Meming @Dr_Meming]

Am I testing my hypothesis or is my hypothesis testing me 🤔

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Targeted degradation of extracellular and membrane proteins is being pursued with therapeutic platforms including sweeping antibodies, LYTACs, ATACs, AbTACs, PROTABs and KineTACs - find out more in this review in the February issue https://t.co/6sD7kFSBkd https://t.co/597yhPFjit